Measles-mumps vaccination in the FRG: an empirical analysis after 14 years of use. II. Tolerability and analysis of spontaneously reported side effects

Fescharek, Reinhard; Quast, U; Maaß, G.; W, Merkle; Schwarz, Sabine

doi:10.1016/0264-410x(90)90245-h

Cited by 38 publications

(10 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This value is consistent with data from a similar US study [2]. In addition, AEFIs associated with the MR component of MMR are likely not to be as important as the AEFIs associated with the measles component [17][18][19]. Thus, we assume that costs of AEFIs associated with MMR are the same as those associated with the measles component of MMR (scenario 1).…”

Section: Methodssupporting

confidence: 71%

Future Savings from Measles Eradication in Industrialized Countries

Carabin¹,

Edmunds²

2003

J INFECT DIS

View full text Add to dashboard Cite

Estimates are made of monetary savings associated with measles eradication in seven industrialized countries. Three scenarios were studied: First, changing from the present two-dose measles-mumps-rubella (MMR) immunization schedule to one-dose of MMR; second, the use of an MMR and mumps-rubella schedule; or third, continuing the present schedule. Results show that the largest savings (US $623 million) would be achieved by changing to a one-dose MMR schedule with an assumption of a 3% discount rate and measles eradication in 2010. The smallest overall savings would result from option 3, by use of a 5% discount rate and the assumption that measles eradication occurs in 2020 ($10 million). These savings are less than previously estimated for the United States, partly because of the assumption that measles vaccines will continue to be delivered in response to possible bioterrorism threats.

show abstract

Section: Methodssupporting

confidence: 71%

Future Savings from Measles Eradication in Industrialized Countries

Carabin¹,

Edmunds²

2003

J INFECT DIS

View full text Add to dashboard Cite

show abstract

“…Minor reactions include local pain, rash, fever, and vomiting. Among postpubertal women who receive MMR vaccine, 25% will have arthropathy [28][29][30][31][32][33][34][35].…”

Section: Methodsmentioning

confidence: 99%

An Economic Analysis of the Current Universal 2-dose measles-mumps-rubella Vaccination Program in the United States

Zhou

Reef

Massoudi

et al. 2004

The Journal of Infectious Diseases

View full text Add to dashboard Cite

To evaluate the economic impact of the current 2-dose measles-mumps-rubella (MMR) vaccination program in the United States, a decision tree-based analysis was conducted with population-based vaccination coverage and disease incidence data. All costs were estimated for a hypothetical US birth cohort of 3803295 infants born in 2001. The 2-dose MMR vaccination program was cost-saving from both the direct cost and societal perspectives compared with the absence of MMR vaccination, with net savings (net present value) from the direct cost and societal perspectives of US dollars 3.5 billion and US dollars 7.6 billion, respectively. The direct and societal benefit-cost ratios for the MMR vaccination program were 14.2 and 26.0. Analysis of the incremental benefit-cost of the second dose showed that direct and societal benefit-cost ratios were 0.31 and 0.49, respectively. Varying the proportion of vaccines purchased and administered in the public versus the private sector had little effect on the results. From both perspectives under even the most conservative assumptions, the national 2-dose MMR vaccination program is highly cost-beneficial and results in substantial cost savings.

show abstract

“…3 Because of the postinfectious nature of the illness, GBS has also been attributed to immunizations. The results of studies on GBS in relation to monovalent or combination measles, mumps, and rubella vaccines, [7][8][9][10][11][12][13][14][15][16][17] influenza vaccine, [18][19][20][21][22] oral polio vaccine, 4,23,24 or diphtheria and tetanus toxoids 25 remain controversial. A committee of the US Institute of Medicine concluded that there was insufficient evidence to accept or reject a causal relationship between measles-mumps-rubella vaccination and GBS.…”

mentioning

confidence: 99%